About

We are pioneering a new era in cancer drug discovery — going beyond proteins and IDRs to drug entire biomolecular condensates, the most elusive cancer drivers.

Our proprietary physics- and AI-powered platform is creating the first foundational model for condensate drugging, enabling precision therapies where conventional drug discovery falls short.

Science

The rules change when proteins assemble — and so must drug discovery

A single bee can sting — but a whole hive can build, defend, and thrive in ways no lone bee ever could.

Biomolecular condensates are like hives: when proteins assemble into condensates, they gain new, emergent properties — coordination, curated compositions, and drug response — that single proteins simply don’t have. 

Because conventional drug discovery is built to target single proteins or isolated IDRs, it simply can’t reach condensates — leaving some of cancer’s most elusive drivers untouchable.

At PhAsIca, we are pioneering the first foundational model for condensate drug discovery — integrating physics, bioinformatics, and AI into a predictive engine that turns condensates into druggable targets. Our platform transforms how the industry tackles cancer’s most elusive drivers, opening a therapeutic space conventional tools can’t reach.

Unlike approaches that focus only on intrinsically disordered regions (IDRs), we capture the full diversity of condensate biology — proteins with ordered and disordered domains, plus RNA, DNA and chromatin. By modeling complete condensates, we uncover emergent rules that govern their role in cancer — rules that single-protein or IDR-only strategies can’t access.